9R5.F Spermosens AB (publ)

Healthcare Diagnostics & Research Frankfurt Exchange
0.0004 EUR
Close of Nov 3, 2026
0.0002 0.0084
Market cap
EUR 1.27M
P/E
-
P/B
0.51x
ROE
-36.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 9R5.F undervalued?

Graham number

The Graham number of Spermosens AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Spermosens AB (publ) fundamental analysis

No fundamental analysis for Spermosens AB (publ) yet.

Spermosens AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Spermosens AB (publ)

Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorporated in 2018 and is headquartered in Lund, Sweden.

Full company profile